Derek J. Maetzold Sells 1,236 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,236 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $20.30, for a total value of $25,090.80. Following the sale, the insider now owns 77,099 shares of the company’s stock, valued at $1,565,109.70. This trade represents a 1.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Castle Biosciences Trading Down 0.8 %

Shares of Castle Biosciences stock opened at $19.94 on Friday. The firm’s 50 day simple moving average is $24.19 and its two-hundred day simple moving average is $28.00. The firm has a market capitalization of $558.46 million, a price-to-earnings ratio of 99.70 and a beta of 0.98. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently made changes to their positions in the company. Barclays PLC grew its stake in Castle Biosciences by 310.7% during the 3rd quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after purchasing an additional 39,567 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after buying an additional 43,241 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Castle Biosciences by 16.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock worth $7,836,000 after buying an additional 39,417 shares during the period. Geode Capital Management LLC increased its holdings in Castle Biosciences by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock worth $17,820,000 after buying an additional 7,004 shares during the period. Finally, State Street Corp raised its position in Castle Biosciences by 9.8% during the 3rd quarter. State Street Corp now owns 680,001 shares of the company’s stock worth $19,394,000 after buying an additional 60,924 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on CSTL. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the company a “buy” rating in a research report on Friday. Robert W. Baird boosted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Finally, Stephens restated an “overweight” rating and issued a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $38.75.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.